Tempus AI Future Growth
Future criteria checks 1/6
Tempus AI is forecast to grow earnings and revenue by 44.1% and 19% per annum respectively. EPS is expected to grow by 44.7% per annum. Return on equity is forecast to be 18.6% in 3 years.
Key information
44.1%
Earnings growth rate
44.68%
EPS growth rate
| Life Sciences earnings growth | 17.2% |
| Revenue growth rate | 19.0% |
| Future return on equity | 18.56% |
| Analyst coverage | Good |
| Last updated | 22 Dec 2025 |
Recent future growth updates
Recent updates
Tempus AI: Plenty Of Growth Catalysts Ahead, Grab It While It's Down
Dec 16After Leaping 29% Tempus AI, Inc. (NASDAQ:TEM) Shares Are Not Flying Under The Radar
Oct 09
Tempus AI, Inc. (NASDAQ:TEM) Looks Just Right With A 28% Price Jump
Aug 15
AstraZeneca And Pathos Partnership Will Expand Precision Medicine
Pharma partnerships and the shift toward AI-driven precision medicine are fueling strong, high-margin revenue growth and expanding Tempus' competitive opportunities.The Tempus AI, Inc. (NASDAQ:TEM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 09Tempus: The AI Engine Powering Healthcare
Apr 20Is Tempus AI (NASDAQ:TEM) A Risky Investment?
Mar 25Tempus AI's Valuation Bakes In Strong Growth - A Hold For Now
Mar 25Tempus AI: The Investment Opportunity Of A Decade, Strong Buy
Mar 18Earnings Update: Here's Why Analysts Just Lifted Their Tempus AI, Inc. (NASDAQ:TEM) Price Target To US$64.11
Feb 27Tempus AI Earnings: A Promising Business, But There Are Risks
Feb 25Tempus AI Is A Buy On Dips In The AI-Driven Healthcare Sector
Feb 18Why Investors Shouldn't Be Surprised By Tempus AI, Inc.'s (NASDAQ:TEM) 82% Share Price Surge
Feb 11Tempus AI: In Vogue, But Better To Wait For Some Retracement
Feb 05Tempus AI: Don't Be Blindly Optimistic On Anything AI
Jan 28Tempus AI: Why I'm Avoiding This Stock In 2025
Jan 21Tempus AI: Recent Weakness Presents Gift Ahead Of The Holidays
Dec 18Tempus AI: Why I'm Buying This AI Stock
Dec 08Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation
Nov 12Tempus: Attempting To Lead The AI Revolution In Healthcare
Oct 29Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'
Aug 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 2,346 | 18 | 278 | 243 | 6 |
| 12/31/2027 | 1,942 | -109 | 137 | 119 | 9 |
| 12/31/2026 | 1,573 | -226 | 2 | 26 | 14 |
| 12/31/2025 | 1,265 | -264 | 220 | -105 | 14 |
| 9/30/2025 | 1,105 | -204 | -249 | -221 | N/A |
| 6/30/2025 | 952 | -200 | -73 | -52 | N/A |
| 3/31/2025 | 803 | -721 | -213 | -193 | N/A |
| 12/31/2024 | 693 | -746 | -211 | -189 | N/A |
| 9/30/2024 | 640 | -801 | -207 | -190 | N/A |
| 6/30/2024 | 596 | -790 | -325 | -292 | N/A |
| 3/31/2024 | 562 | -293 | -284 | -249 | N/A |
| 12/31/2023 | 532 | -266 | -249 | -214 | N/A |
| 9/30/2023 | 485 | -276 | -266 | -233 | N/A |
| 12/31/2022 | 321 | -334 | -187 | -168 | N/A |
| 9/30/2022 | 293 | -325 | -192 | -173 | N/A |
| 12/31/2021 | 258 | -298 | -224 | -212 | N/A |
| 9/30/2021 | 285 | -296 | -205 | -193 | N/A |
| 6/30/2021 | 284 | -286 | -199 | -188 | N/A |
| 3/31/2021 | 236 | -270 | -209 | -198 | N/A |
| 12/31/2020 | 188 | -254 | -220 | -207 | N/A |
| 12/31/2019 | 62 | -148 | -134 | -117 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TEM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TEM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TEM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TEM's revenue (19% per year) is forecast to grow faster than the US market (10.4% per year).
High Growth Revenue: TEM's revenue (19% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TEM's Return on Equity is forecast to be low in 3 years time (18.6%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/04 07:40 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tempus AI, Inc. is covered by 19 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |